company background image
IXC

Invex TherapeuticsASX:IXC Stock Report

Market Cap

AU$53.4m

7D

7.5%

1Y

-25.0%

Updated

19 Oct, 2021

Data

Company Financials
IXC fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

IXC Overview

Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia.

Price History & Performance

Summary of all time highs, changes and price drops for Invex Therapeutics
Historical stock prices
Current Share PriceAU$0.72
52 Week HighAU$0.51
52 Week LowAU$1.08
Beta1.1
1 Month Change5.11%
3 Month Change21.01%
1 Year Change-25.00%
3 Year Changen/a
5 Year Changen/a
Change since IPO-33.02%

Recent News & Updates

Sep 27
We're Interested To See How Invex Therapeutics (ASX:IXC) Uses Its Cash Hoard To Grow

We're Interested To See How Invex Therapeutics (ASX:IXC) Uses Its Cash Hoard To Grow

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Mar 31
We're Hopeful That Invex Therapeutics (ASX:IXC) Will Use Its Cash Wisely

We're Hopeful That Invex Therapeutics (ASX:IXC) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Shareholder Returns

IXCAU PharmaceuticalsAU Market
7D7.5%2.8%1.7%
1Y-25.0%4.9%20.3%

Return vs Industry: IXC underperformed the Australian Pharmaceuticals industry which returned 4.9% over the past year.

Return vs Market: IXC underperformed the Australian Market which returned 20.3% over the past year.

Price Volatility

Is IXC's price volatile compared to industry and market?
IXC volatility
IXC Beta1.1
Industry Beta1.3
Market Beta1

Stable Share Price: IXC is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: IXC's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2019n/an/ahttps://www.invextherapeutics.com

Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase II clinical trial. The company was incorporated in 2019 and is based in Subiaco, Australia.

Invex Therapeutics Fundamentals Summary

How do Invex Therapeutics's earnings and revenue compare to its market cap?
IXC fundamental statistics
Market CapAU$53.36m
Earnings (TTM)-AU$2.28m
Revenue (TTM)n/a

0x

P/S Ratio

-23.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IXC income statement (TTM)
RevenueAU$0
Cost of RevenueAU$0
Gross ProfitAU$0
ExpensesAU$2.28m
Earnings-AU$2.28m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.03
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did IXC perform over the long term?

See historical performance and comparison

Valuation

Is Invex Therapeutics undervalued compared to its fair value and its price relative to the market?

1.69x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate IXC's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate IXC's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: IXC is unprofitable, so we can't compare its PE Ratio to the Oceanic Pharmaceuticals industry average.

PE vs Market: IXC is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IXC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IXC is good value based on its PB Ratio (1.7x) compared to the AU Pharmaceuticals industry average (3.5x).


Future Growth

How is Invex Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

67.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Invex Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Invex Therapeutics performed over the past 5 years?

32.0%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: IXC is currently unprofitable.

Growing Profit Margin: IXC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if IXC's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare IXC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IXC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.4%).


Return on Equity

High ROE: IXC has a negative Return on Equity (-7.12%), as it is currently unprofitable.


Financial Health

How is Invex Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: IXC's short term assets (A$32.7M) exceed its short term liabilities (A$658.6K).

Long Term Liabilities: IXC has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: IXC is debt free.

Reducing Debt: IXC has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IXC has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: IXC has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 35% each year


Dividend

What is Invex Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate IXC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IXC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IXC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IXC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IXC's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average board tenure


CEO

Invex Therapeutics has no CEO, or we have no data on them.


Board Members

Experienced Board: IXC's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Invex Therapeutics Ltd's employee growth, exchange listings and data sources


Key Information

  • Name: Invex Therapeutics Ltd
  • Ticker: IXC
  • Exchange: ASX
  • Founded: 2019
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$53.359m
  • Shares outstanding: 75.15m
  • Website: https://www.invextherapeutics.com

Location

  • Invex Therapeutics Ltd
  • 38 Rowland Street
  • Level 1
  • Subiaco
  • Western Australia
  • 6008
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/19 07:03
End of Day Share Price2021/10/19 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.